News

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...
Gilead and its partners' efforts to distribute generic lenacapavir could be derailed by cuts in international aid budgets ...
GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.
Globally, 1.3 million people were newly infected with HIV in 2023, according to the latest estimates. But getting lenacapavir to low- and middle-income countries may take time.
The FDA approved lenacapavir last week. Patients need just two injections of it a year to get that protection, but as NPR's Jonathan Lambert explains, its high price could limit its power to stop ...
LEILA FADEL, HOST: A newly approved drug gives almost total protection against getting HIV. The FDA approved lenacapavir last week. Patients need just two injections of it a year to get that ...
A newly approved drug gives almost total protection against getting HIV. The FDA approved lenacapavir last week. Patients need just two injections of it a year to get that protection, but as NPR's ...
06/24/2025 The US has approved lenacapavir for HIV prevention. However, experts worry that cuts to the health budget will "squander" the drug's chance of reducing infections.
The FDA approved lenacapavir, an HIV prevention drug based on University of Utah biochemist Wesley Sundquist's research. Developed by Gilead Sciences, lenacapavir binds HIV's protein shell ...
Lenacapavir’s six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills.
WHO guidelines for injectable lenacapavir are scheduled for release on July 14, 2025, during the International AIDS Conference in Kigali, sources said. The FDA approval also enables the WHO ...
Lenacapavir is the second long-acting drug approved to prevent HIV. The first, Apretude, is given every two months and is used by about 21,000 Americans.